Ann: Consolidation/Split - OSP, page-33

Mikes response, didn't answer the questions so will decide if will repond asking for greater detail on actual plans.

Scott,

Thank you for your message and for your holdings in Osprey. I have answered your questions below.

• what strategy are the Osprey board undertaking to facilitate greater investment into Ospreys future by large investors once the consolidation is done?. We engage in the US/EU/AU/NZ/Sing/HK to educate investors on Osprey business and investment thesis. In 2021 we have issued over 20 press releases and 4 investor presentations (slides released) at specialty investor meetings in the US and EU. We will continue to aggressively pursue this activity the rest of 2021 and 2022
• what actions are the Osprey board undertaking to increase greater uptake of core products with key global distributors, i.e. GE, Premier and RHCG and what does that trajectory look like? We are thrilled to have a partners like GE Healthcare in EMEA. We work closely with GE to insuring commercial success. Europe’s COVID recover is underway and GE is now regaining hospital access which to this point has been difficult. Despite these EU COVID challenges we were pleased to report in 2Q that GE represented 22% of all units sold worldwide. In Australia RHCG commercial launch continues to be affected by a slower rebound from COVID-19 and limited access for their reps to hospitals.
• capital looks good for 4 -5 qtrs based on reports, given income doesn't cover a qrt, what are the boards actions in addressing this without asking for capital raise and further dilution once the consolidation is done. The BoD and Management team are focus on increasing revenues with appropriate spending levels. Our primary Company goal is to reach cash flow positive as soon as possible.

Thanks again for your questions; don’t hesitate to let me know if you have any further questions.

All the best!

Mike McCormick

President and CEO